Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer

Bone Marrow Transplantation volume 45, pages 464–467 (2010)Cite this article

Abstract

Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) allo-SCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m2 at days −5 to −1) and CY (60 mg/kg at days −2, −1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43–509 days) and 303 days (122–1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895.

    Article  CAS  Google Scholar 

  3. Huugen D, Schouten HC, Bos GM . Advantages and limitations of (non-) myeloablative allogeneic stem cell transplantation. Neth J Med 2002; 60: 162–169.

    CAS  PubMed  Google Scholar 

  4. Buffart TE, Janssen JJWM, Huijgens PC . Reduced-intensity conditioning regimens in malignant haematological diseases. Neth J Med 2005; 63: 43–51.

    CAS  PubMed  Google Scholar 

  5. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756.

    Article  CAS  Google Scholar 

  6. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178–185.

    Article  PubMed  Google Scholar 

  7. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.

    Article  CAS  Google Scholar 

  8. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810–1814.

    Article  CAS  Google Scholar 

  9. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J . Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044.

    Article  CAS  PubMed  Google Scholar 

  10. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang M-J et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008; 41: 537–545.

    Article  CAS  PubMed  Google Scholar 

  11. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology 2008; 5: 256–267.

    Article  CAS  PubMed  Google Scholar 

  12. Storb R, Deeg H, Farewell V, Doney K, Appelbaum F, Beatty P et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119–125.

    CAS  Google Scholar 

  13. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  Google Scholar 

  14. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267.

    CAS  Google Scholar 

  15. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–320.

    Article  PubMed  Google Scholar 

  16. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886–3892.

    Article  PubMed  Google Scholar 

  17. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829.

    Article  CAS  PubMed  Google Scholar 

  18. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234.

    Article  CAS  PubMed  Google Scholar 

  19. Seidman AD, O′Shaughnessy J, Misset J-L . Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7: 20–28.

    Article  CAS  PubMed  Google Scholar 

  20. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands

    A J H M Fleskens, G M J Bos, M van Gelder & H C Schouten

  2. Division of Medical Oncology, Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands

    R I Lalisang & R L H Jansen

Authors
  1. A J H M Fleskens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R I Lalisang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G M J Bos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M van Gelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R L H Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H C Schouten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H C Schouten.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleskens, A., Lalisang, R., Bos, G. et al. HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Bone Marrow Transplant 45, 464–467 (2010). https://doi.org/10.1038/bmt.2009.178

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.178

Keywords

This article is cited by

Search

Advanced search

Quick links